Joint with: Neuroimmune Interactions: Nervous System and Immune Cell Heterogeneity in Health and Disease
Neurodegenerative Diseases
Jun 03–06, 2024 | Santa Fe Community Convention Center, Santa Fe, NM, United States
Scientific Organizers:
Leonard Petrucelli, Stacie Weninger and Soyon Hong
In Person
Jun 03–06, 2024 | Santa Fe Community Convention Center, Santa Fe, NM, United States
Scientific Organizers:
Leonard Petrucelli, Stacie Weninger and Soyon Hong
Available Formats:
Supported by the Directors' Fund
In Person
***Meeting program subject to change.
Available Formats: = In PersonMerchandise Options
Registration Options
Booking Function
Fundraising
Monday, June 3, 2024
Arrival and Registration
4:00–8:00 PM
Sweeney Ballroom Foyer
Welcome Mixer
6:00–8:00 PM
Lobby
Tuesday, June 4, 2024
Breakfast
7:00–8:00 AM
Sweeney F, Main Level Breakouts
Poster Setup
7:30–8:00 AM
Sweeney Ballroom F
Welcome and Keynote Session (Joint)
8:00–9:30 AM
Sweeney Ballroom A-E
Tony Wyss-Coray, Stanford University School of Medicine
Aging, the Immune System and Neurodegeneration
Aging, the Immune System and Neurodegeneration
Beth Stevens, Boston Children's Hospital, Harvard Medical School
Connecting Human Microglia States to Function in Health and Disease
Connecting Human Microglia States to Function in Health and Disease
Poster Viewing
8:00–7:00 PM
Sweeney Ballroom F
Coffee Break
9:30–9:50 AM
Sweeney Ballroom Foyer
Immune-CNS Interactions in Neurodegeneration (Joint)
9:50–11:15 AM
Sweeney Ballroom A-E
Christopher K. Glass, University of California, San Diego
Transcriptional Regulation of Macrophage Development
Transcriptional Regulation of Macrophage Development
S. Pablo Sardi, Sanofi
Therapeutic Development for Neurodegenerative Disorders
Therapeutic Development for Neurodegenerative Disorders
Anne Schaefer, Icahn School of Medicine at Mount Sinai, MPI Ageing
Epigenetic Regulation of Microglia
Epigenetic Regulation of Microglia
Lunch
11:15–12:15 PM
Sweeney F, Main Level Breakouts
Poster Session 1
11:45–2:30 PM
Sweeney Ballroom F
Workshop 1: Immune-CNS Interactions in Neurodegeneration
2:30–4:30 PM
Sweeney Ballroom A-B
Lynn van Olst, Northwestern University
Spatial Transcriptomics Reveals Neuroimmune Mechanisms of Aβ Clearance in Immunized Alzheimer’s Disease Patients
Spatial Transcriptomics Reveals Neuroimmune Mechanisms of Aβ Clearance in Immunized Alzheimer’s Disease Patients
Georg Werner, Ludwig-Maximilians-Universität München
Single Cell Analysis Reveals a Neurodegeneration Specific Microglia Population Resistant to CSF1R Inhibition in a Mouse Model with FTLD-like Pathology
Single Cell Analysis Reveals a Neurodegeneration Specific Microglia Population Resistant to CSF1R Inhibition in a Mouse Model with FTLD-like Pathology
Urs Langen, Hoffmann-La Roche AG
Beyond the Shuttle: Advances in Brain Delivery of Biologics for the Treatment of Neurodegenerative Diseases
Beyond the Shuttle: Advances in Brain Delivery of Biologics for the Treatment of Neurodegenerative Diseases
Ravi Jagasia, Pharma Research and Early Development
Genome-Wide CRISPR-Cas9 Based Screening for Modifiers of Lysosomal GCase Activity Uncovers Candidate Risk Factors for Parkinson Disease
Genome-Wide CRISPR-Cas9 Based Screening for Modifiers of Lysosomal GCase Activity Uncovers Candidate Risk Factors for Parkinson Disease
Kyle J Travaglini, Allen Institute for Brain Science
An Integrated Multimodal Cell Atlas of Alzheimer's Disease
An Integrated Multimodal Cell Atlas of Alzheimer's Disease
Maylin Fu, Stanford University
Controlling Endogenous mRNA Localization in the Peripheral and Central Nervous Systems in vivo
Controlling Endogenous mRNA Localization in the Peripheral and Central Nervous Systems in vivo
Philip L. De Jager, Columbia University Medical Center
Human Microglia Expressing High Levels of CD74 Expression are Associated with Activation and Cognitive Decline
Human Microglia Expressing High Levels of CD74 Expression are Associated with Activation and Cognitive Decline
Ian Peikon, Cajal Neuroscience
Dire Straits: Loss of Translational Regulation of SNCA by Iron Unifies the Genetics of PD and LBD at the SNCA Locus
Dire Straits: Loss of Translational Regulation of SNCA by Iron Unifies the Genetics of PD and LBD at the SNCA Locus
Coffee Available
4:30–5:00 PM
Sweeney Ballroom Foyer
Neuroimmune Interactions Relevant to NDD
5:00–7:00 PM
Sweeney Ballroom A-B
Kate Monroe, Denali Therapeutics
Leveraging Human Genetics for Novel Therapeutic Approaches for Alzheimer's Disease
Leveraging Human Genetics for Novel Therapeutic Approaches for Alzheimer's Disease
Christian Haass, Ludwig-Maximilians University Munich
PGRN/ApoE
PGRN/ApoE
David M. Holtzman, Washington University
Role of APOE in Modulating the Innate and Adaptive Immune Response in Neurodegeneration
Role of APOE in Modulating the Innate and Adaptive Immune Response in Neurodegeneration
August Yue Huang, Boston Children's Hospital
Short Talk: Short Talk: Alzheimer’s Disease Microglia Exhibit Enriched Proliferation-related Clonal Somatic Mutations Associated with Inflammatory States
Short Talk: Short Talk: Alzheimer’s Disease Microglia Exhibit Enriched Proliferation-related Clonal Somatic Mutations Associated with Inflammatory States
John D. Fryer, Mayo Clinic
Short Talk: Short Talk: Anti-amyloid Immunotherapy Induces Sustained Microglial and Immune Alterations
Short Talk: Short Talk: Anti-amyloid Immunotherapy Induces Sustained Microglial and Immune Alterations
On Own for Dinner
7:00–8:00 PM
Wednesday, June 5, 2024
Breakfast
7:00–8:00 AM
Sweeney F, Main Level Breakouts
Molecular Mechanisms in NDD
8:00–11:00 AM
Sweeney Ballroom A-B
Soyon Hong, University College London
Neuroimmune Signaling Across Gut-Brain Axis Modulates Brain Synucleinopathy
Neuroimmune Signaling Across Gut-Brain Axis Modulates Brain Synucleinopathy
Nicholas T. Seyfried, Emory University School of Medicine
Integrated Proteomics for Therapeutic Target and Biomarker Discovery in Alzheimer’s Disease
Integrated Proteomics for Therapeutic Target and Biomarker Discovery in Alzheimer’s Disease
Leonard Petrucelli, Mayo Clinic Jacksonville
Tmem/PGRN
Tmem/PGRN
Bakhos Tadros, Baylor College of Medicine
Short Talk: Short Talk: LMO7 Modulates Tau Levels by Regulating CHIP-BAG5 Interplay: Novel Insights into Tauopathy Mechanisms
Short Talk: Short Talk: LMO7 Modulates Tau Levels by Regulating CHIP-BAG5 Interplay: Novel Insights into Tauopathy Mechanisms
Alexi Nott, Imperial College London
Short Talk: Short Talk: Vascular–immune Epigenetic Mechanisms Underlying Age-related Brain Disorders
Short Talk: Short Talk: Vascular–immune Epigenetic Mechanisms Underlying Age-related Brain Disorders
Dalya Rosner, Alector
Short Talk: Short Talk: The Alzheimer’s Risk Genes MS4A4A and MS4A6A Cooperate to Regulate Key Microglial Functions
Short Talk: Short Talk: The Alzheimer’s Risk Genes MS4A4A and MS4A6A Cooperate to Regulate Key Microglial Functions
Roy R. Parker, HHMI/University of Colorado
Short Talk: Short Talk: Polyserine Domain RNA-binding Proteins as Cellular Factors Enhancing Tau Aggregation
Short Talk: Short Talk: Polyserine Domain RNA-binding Proteins as Cellular Factors Enhancing Tau Aggregation
Coffee Break
9:00–9:20 AM
Sweeney Ballroom Foyer
Poster Setup
11:00–1:00 PM
Sweeney Ballroom F
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Sweeney Ballroom F
Career Roundtable (Joint)
2:30–4:30 PM
Sweeney Ballroom D-E
Francesca Odoardi, University Medical Center Göttingen
Group Leader & Professor
Group Leader & Professor
Suman Jayadev, University of Washington
Associate Professor, Director and Neurogeneticist
Associate Professor, Director and Neurogeneticist
Arya Biragyn, NIA, National Institutes of Health
Senior Investigator
Senior Investigator
Sarah DeVos, Curie.Bio
Drug Maker in Residence
Drug Maker in Residence
Tim Spencer, Journal of Cell Biology
Executive Editor
Executive Editor
Coffee Available
4:30–5:00 PM
Sweeney Ballroom Foyer
Susceptibility vs. Resilience: Understanding Region Vulnerability in NDD
5:00–7:00 PM
Sweeney Ballroom A-B
Cagla Eroglu, Duke University Medical Center
In vivo Proteomic Tools TurboID
In vivo Proteomic Tools TurboID
Henne Holstege, Amsterdam UMC
Cognitively Healthy Centenarians are Genetically Protected Against Alzheimer’s Disease
Cognitively Healthy Centenarians are Genetically Protected Against Alzheimer’s Disease
James Gorman, Wyss Institute
Targeting Known and Novel Receptors to Deliver Drugs for Neurodegenerative Diseases
Targeting Known and Novel Receptors to Deliver Drugs for Neurodegenerative Diseases
Guoyan Zhao, Washington University
Short Talk: Short Talk: Transcriptomic Changes in Lewy Body Disease and Alzheimer's Disease Linked to Selective Regional and Neuronal Vulnerability
Short Talk: Short Talk: Transcriptomic Changes in Lewy Body Disease and Alzheimer's Disease Linked to Selective Regional and Neuronal Vulnerability
Mohammad Abbasi, Arizona State University
Short Talk: Short Talk: Unveiling Microglial Heterogeneity in Spatial Context
Short Talk: Short Talk: Unveiling Microglial Heterogeneity in Spatial Context
Social Hour with Lite Bites
7:00–8:00 PM
Sweeney F, Main Level Breakouts
Poster Session 2
7:30–10:00 PM
Sweeney Ballroom F
Thursday, June 6, 2024
Breakfast
7:00–8:00 AM
Sweeney F, Main Level Breakouts
Modelling Human NDD in a Dish
8:00–11:00 AM
Sweeney Ballroom A-B
Tarja Malm, University of Eastern Finland
Modeling Early Alzheimer’s Disease in Human Context
Modeling Early Alzheimer’s Disease in Human Context
Irene Faravelli, Harvard University
Chimeroids as Avatars to Investigate Brain Diseases
Chimeroids as Avatars to Investigate Brain Diseases
Martin Kampmann, University of California, San Francisco
Elucidating Mechanisms and Therapeutic Targets for Neurodegenerative Diseases by CRISPR-Based Functional Genomics
Elucidating Mechanisms and Therapeutic Targets for Neurodegenerative Diseases by CRISPR-Based Functional Genomics
Nilesh Sharma, University of Calgary
Short Talk: Short Talk: Metabolic Perturbation in Ependymal Cells Leads to Progressive Peri-ventricular Pathology and Recapitulates Alzheimer’s Disease Pathogenesis
Short Talk: Short Talk: Metabolic Perturbation in Ependymal Cells Leads to Progressive Peri-ventricular Pathology and Recapitulates Alzheimer’s Disease Pathogenesis
Jean Paul Chadarevian, UC Irvine
Short Talk: Short Talk: Therapeutic Potential of Human Microglial Transplantation in a Chimeric Model of CSF1R-related Leukoencephalopathy
Short Talk: Short Talk: Therapeutic Potential of Human Microglial Transplantation in a Chimeric Model of CSF1R-related Leukoencephalopathy
Lulu Jiang, University of Virginia
Short Talk: Short Talk: The Innovative Neuron-Glial Brain Assembloid Model of Alzheimer’s Disease Reveals the Differential Role of ApoE Isoforms in Pathological Tau Propagation
Short Talk: Short Talk: The Innovative Neuron-Glial Brain Assembloid Model of Alzheimer’s Disease Reveals the Differential Role of ApoE Isoforms in Pathological Tau Propagation
Mireia Gomez-Budia, University of Eastern Finland
Short Talk: Short Talk: Unravelling LTP-like Synaptic Plasticity in Human Cortical Biopsies on Microelectrode Arrays
Short Talk: Short Talk: Unravelling LTP-like Synaptic Plasticity in Human Cortical Biopsies on Microelectrode Arrays
Coffee Break
9:00–9:20 AM
Sweeney Ballroom Foyer
Poster Setup
11:00–1:00 PM
Sweeney Ballroom F
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Sweeney Ballroom F
Workshop 2: Steps Toward Precision Medicine for NDD
2:30–4:30 PM
Sweeney Ballroom A-B
Jordan Marks, Mayo Clinic
TMEM106B Risk SNP Alters Disease Duration and Fibril Deposition in FTLD-TDP
TMEM106B Risk SNP Alters Disease Duration and Fibril Deposition in FTLD-TDP
Zhe Zhang, John Hopkins University
PTPσ-Mediated PI3P Regulation as a Therapeutic Strategy for C9ORF72-ALS/FTD
PTPσ-Mediated PI3P Regulation as a Therapeutic Strategy for C9ORF72-ALS/FTD
Tina Schwabe, Nine Square Therapeutics
Developing Parkin Activators to Enhance Mitochondrial Function for the Treatment of Parkinson’s Disease
Developing Parkin Activators to Enhance Mitochondrial Function for the Treatment of Parkinson’s Disease
Francesca Cignarella, Foundation for the National Institutes of Health (FNIH)
Enabling a Precision Medicine Approach to Target and Biomarker Discovery in Alzheimer’s Disease: Accelerating Medicines Partnership® Alzheimer’s Disease (AMP AD)
Enabling a Precision Medicine Approach to Target and Biomarker Discovery in Alzheimer’s Disease: Accelerating Medicines Partnership® Alzheimer’s Disease (AMP AD)
Tong Wu, Washington University in St. Louis
Targeting SARM1 Inhibition Provides a Promising Therapeutic Strategy for DNA Damage-Induced Neurodegenerative Diseases, Including Amyotrophic Lateral Sclerosis (ALS)
Targeting SARM1 Inhibition Provides a Promising Therapeutic Strategy for DNA Damage-Induced Neurodegenerative Diseases, Including Amyotrophic Lateral Sclerosis (ALS)
Laura Koenig, Harvard Medical School
TYK2 Kinase as a Novel Therapeutic Target in Alzheimer’s Disease
TYK2 Kinase as a Novel Therapeutic Target in Alzheimer’s Disease
Karthik A Raju, Denali Therapeutics
GPR34 Loss-of-function Rescues TREM2 Metabolic Dysfunction and Promotes Responsive Microglial States
GPR34 Loss-of-function Rescues TREM2 Metabolic Dysfunction and Promotes Responsive Microglial States
Jing Guo, NICO Therapeutics
Decreased Lipidated ApoE-receptor Interactions Confer Protection against Pathogenicity of ApoE and its Lipid Cargoes
Decreased Lipidated ApoE-receptor Interactions Confer Protection against Pathogenicity of ApoE and its Lipid Cargoes
Coffee Available
4:30–5:00 PM
Sweeney Ballroom Foyer
Designing Better: Steps Toward Precision Medicine for NDD
5:00–6:45 PM
Sweeney Ballroom A-B
Fiona C. Elwood, Janssen R&D
Precision Medicine in Neurodegeneration
Precision Medicine in Neurodegeneration
Jia Tay, Prime Medicine, Inc.
Prime Editing as a Curative Therapeutic Approach for Neurodegenerative Diseases
Prime Editing as a Curative Therapeutic Approach for Neurodegenerative Diseases
Bruno Godinho, Atalanta Therapeutics
Addressing CNS Indications using a Novel Di-siRNA Modality for Improved Potency, Distribution, and Duration
Addressing CNS Indications using a Novel Di-siRNA Modality for Improved Potency, Distribution, and Duration
Jeffrey D. Rothstein, Johns Hopkins University
ALS and Neurodegeneration Starts at the Nuclear Pore: Insights and Therapy for ALS and Dementia
ALS and Neurodegeneration Starts at the Nuclear Pore: Insights and Therapy for ALS and Dementia
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Sweeney Ballroom A-B
Social Hour with Lite Bites
7:00–8:00 PM
Sweeney F, Main Level Breakouts
Poster Session 3
7:30–10:00 PM
Sweeney Ballroom F
Friday, June 7, 2024
Departure
7:00–11:59 PM
Subscribe for Updates